Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
The impact of mental illness on sexual dysfunction
Z. Zemishlany
*
,
A. Weizman
*
Corresponding author for this work
Clinical Departments
Geha Mental Health Center
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
172
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The impact of mental illness on sexual dysfunction'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Neuroscience
Antidepressant
100%
Selective Serotonin Reuptake Inhibitor
100%
Drug Therapy
100%
Psychopathology
100%
Mirtazapine
100%
Schizophrenia
100%
Negative Syndrome
50%
Personality Disorder
50%
Eating Disorder
50%
Phosphodiesterase Inhibitor
50%
Reboxetine
50%
Borderline Personality Disorder
50%
Bupropion
50%
Nefazodone
50%
Receptor
50%
Mianserin
50%
Side Effect
50%
Keyphrases
Mental Disorders
100%
Sexual Dysfunction
100%
Pharmacotherapy
22%
Second-generation Antipsychotics
22%
Antidepressants
22%
Psychopathology
22%
Selective Serotonin Reuptake Inhibitors
22%
Mirtazapine
22%
D2 Receptor
11%
Personality Disorders
11%
Psychiatric Patients
11%
Eating Disorders
11%
Phosphodiesterase Inhibitors
11%
Negative Symptoms of Schizophrenia
11%
Sexual Relationships
11%
Reboxetine
11%
Erectile Function
11%
Mianserin
11%
Antagonistic Activity
11%
Nefazodone
11%
Borderline Personality Disorder
11%
Bupropion
11%
Orgasmic Function
11%
5′-Phosphodiesterase
11%
Sexual Side Effects
11%
Schizophrenic
11%
Psychosexual Therapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Mental Diseases
100%
Sexual Dysfunction
100%
Pharmacotherapy
22%
Antidepressant
22%
Mirtazapine
22%
Selective Serotonin Reuptake Inhibitor
22%
Schizophrenia
22%
Deterioration
11%
Receptor
11%
Eating Disorder
11%
Negative Syndrome
11%
Borderline State
11%
Reboxetine
11%
Mianserin
11%
Serotonin 2 Antagonist
11%
Phosphodiesterase V Inhibitor
11%
Bupropion
11%
Nefazodone
11%
Personality Disorder
11%
Side Effect
11%